Alanna J. Church

Publications

1. BK Polyomavirus-Associated Kidney and Bladder Carcinomas Following Heart and Lung Transplantation in Childhood. Pediatr Dev Pathol. 2026 Mar-Apr; 29(2):128-135. View Abstract
2. MYC amplification and MYC protein expression are poor prognostic markers in pediatric and young adult osteosarcoma. Cancer. 2025 Nov 15; 131(22):e70161. View Abstract
3. Mutational Signature in Cancers Following Solid Organ or Allogeneic Stem Cell Transplantation. Mod Pathol. 2026 Jan; 39(1):100921. View Abstract
4. Molecular profiling in paediatric hepatocellular adenomas: phenotypic correlations and clinical significance. Histopathology. 2026 Feb; 88(3):648-663. View Abstract
5. Patient-centered integration of tumor and germline genetic results can improve cancer care. Nat Med. 2025 Oct; 31(10):3248-3251. View Abstract
6. Clinical Implementation of Matched Tumor/Germline Sequencing Improves Accuracy of Tumor Genomic Profiling and Therapeutic Recommendations. J Mol Diagn. 2025 Oct; 27(10):969-988. View Abstract
7. A New Era for Molecular Diagnostics: Reclaiming Strategic Vision for Patient Care. J Mol Diagn. 2025 Jul; 27(7):539-540. View Abstract
8. Pediatric-type Myoid Neoplasms of Somatic Soft Tissue: A Clinicopathological and Molecular Genetic Study of 78 Tumors, Highlighting Indolent Clinical Behavior and Frequent SRF Gene Rearrangements. Mod Pathol. 2025 May; 38(5):100722. View Abstract
9. Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children's Oncology Group. medRxiv. 2025 Jan 20. View Abstract
10. Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823). J Clin Oncol. 2025 Apr; 43(10):1188-1197. View Abstract
11. Molecular Diagnostics in Pediatric Pathology Practice: Current Trends and Development. Surg Pathol Clin. 2025 Jun; 18(2):407-417. View Abstract
12. The implementation of molecular tumor profiling in the practice of pediatric cancer pathology: The pathologists' experience. Pediatr Blood Cancer. 2025 Jan; 72(1):e31370. View Abstract
13. Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Aug 22; 15(1):7218. View Abstract
14. Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 08; 22(6):413-433. View Abstract
15. ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs. Cancer Res. 2024 Jul 15; 84(14):2247-2264. View Abstract
16. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Jul 11; 15(1):5837. View Abstract
17. Promise and Perils of Precision Oncology for Patients With Pediatric and Young Adult Sarcomas. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e432794. View Abstract
18. Molecular Alterations in Pediatric Solid Tumors. Clin Lab Med. 2024 Jun; 44(2):277-304. View Abstract
19. Clinical and immunophenotype correlating with response to immunotherapy in paediatric patients with primary liver carcinoma. A case series. EBioMedicine. 2024 Jun; 104:105147. View Abstract
20. Section E6.7-6.12 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in solid tumors. Genet Med. 2024 04; 26(4):101070. View Abstract
21. CTNNB1 and APC Mutations in Sinonasal Myxoma : Expanding the Spectrum of Tumors Driven By WNT/ß-catenin Pathway. Am J Surg Pathol. 2023 11 01; 47(11):1291-1300. View Abstract
22. Next generation sequencing aids diagnosis and management in a case of encephalocraniocutaneous lipomatosis. Pediatr Dermatol. 2024 Jan-Feb; 41(1):76-79. View Abstract
23. STK11 Adnexal Tumor in an Adolescent Female: Diagnostic Pitfalls of a Recently Described Entity. Pediatr Dev Pathol. 2023 Sep-Oct; 26(5):486-493. View Abstract
24. Splenic Lymphatic Malformation With Papillary Endothelial Proliferation: A Rare Histologic Variant or a Unique Entity? Am J Surg Pathol. 2023 08 01; 47(8):915-925. View Abstract
25. A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. Cancer Med. 2023 06; 12(12):13300-13308. View Abstract
26. Current Utilization of Electron Microscopy in the Pediatric Pathology Setting: A Survey by the SPP Practice Committee. Pediatr Dev Pathol. 2023 Jul-Aug; 26(4):411-422. View Abstract
27. Genomic analysis reveals germline and somatic PDGFRB variants with clinical implications in familial infantile myofibromatosis. Pediatr Blood Cancer. 2023 06; 70(6):e30262. View Abstract
28. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023 03; 7:e2200334. View Abstract
29. Expanding the Spectrum of Perioral Myogenic Tumors in Pediatric Patients: An SRF::NCOA2 Fused Perivascular Tumor of the Philtrum. Pediatr Dev Pathol. 2023 Jan-Feb; 26(1):65-71. View Abstract
30. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol. 2022 11; 6:e2200390. View Abstract
31. Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group. Br J Cancer. 2022 12; 127(12):2220-2226. View Abstract
32. Special Considerations in the Molecular Diagnostics of Pediatric Neoplasms. Clin Lab Med. 2022 09; 42(3):349-365. View Abstract
33. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 08; 28(8):1581-1589. View Abstract
34. Gamma Secretase Inhibition for a Child With Metastatic Glomus Tumor and Activated NOTCH1. JCO Precis Oncol. 2022 06; 6:e2200099. View Abstract
35. Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy. Histopathology. 2022 Aug; 81(2):215-227. View Abstract
36. Thyroid Nodules in Children With Familial Adenomatous Polyposis. Am J Gastroenterol. 2022 07 01; 117(7):1166-1168. View Abstract
37. Standardized evidence-based approach for assessment of oncogenic and clinical significance of NTRK fusions. Cancer Genet. 2022 06; 264-265:50-59. View Abstract
38. Genomic comparison of malignant melanoma and atypical Spitz tumor in the pediatric population. Pediatr Dermatol. 2022 May; 39(3):409-419. View Abstract
39. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5. View Abstract
40. Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy. Pediatrics. 2021 12 01; 148(6). View Abstract
41. Assessment of BCOR Internal Tandem Duplications in Pediatric Cancers by Targeted RNA Sequencing. J Mol Diagn. 2021 10; 23(10):1269-1278. View Abstract
42. Molecular Alterations in Pediatric Solid Tumors. Surg Pathol Clin. 2021 Sep; 14(3):473-492. View Abstract
43. A Curriculum for Genomic Education of Molecular Genetic Pathology Fellows: A Report of the Association for Molecular Pathology Training and Education Committee. J Mol Diagn. 2021 10; 23(10):1218-1240. View Abstract
44. Fibrolamellar carcinoma: An entity all its own. Curr Probl Cancer. 2021 08; 45(4):100770. View Abstract
45. Undifferentiated Embryonal Sarcoma of the Liver With Rhabdoid Morphology Mimicking Carcinoma: Expanding the Morphologic Spectrum or a Distinct Variant? Pediatr Dev Pathol. 2021 Nov-Dec; 24(6):564-569. View Abstract
46. Natural History of Thyroid Disease in Children with PTEN Hamartoma Tumor Syndrome. J Clin Endocrinol Metab. 2021 03 08; 106(3):e1121-e1130. View Abstract
47. A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine. Pediatr Blood Cancer. 2021 04; 68(4):e28780. View Abstract
48. PD-1 and PD-L1 Expression in Osteosarcoma: Which Specimen to Evaluate? J Pediatr Hematol Oncol. 2020 11; 42(8):482-487. View Abstract
49. Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing. JCO Precis Oncol. 2020 Nov; 4:1084-1097. View Abstract
50. New molecular insights into the pathogenesis of lipoblastomas: clinicopathologic, immunohistochemical, and molecular analysis in pediatric cases. Hum Pathol. 2020 10; 104:30-41. View Abstract
51. Making the most of small samples: Optimization of tissue allocation of pediatric solid tumors for clinical and research use. Pediatr Blood Cancer. 2020 09; 67(9):e28326. View Abstract
52. Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms. Histopathology. 2020 Jun; 76(7):1032-1041. View Abstract
53. Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma. Blood Adv. 2020 04 14; 4(7):1265-1269. View Abstract
54. DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020 10; 33(10):1910-1921. View Abstract
55. Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. Clin Cancer Res. 2020 06 15; 26(12):2882-2890. View Abstract
56. Recurrent and novel USP6 fusions in cranial fasciitis identified by targeted RNA sequencing. Mod Pathol. 2020 05; 33(5):775-780. View Abstract
57. A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. Thyroid. 2019 11; 29(11):1704-1707. View Abstract
58. A Distinctive Genomic and Immunohistochemical Profile for NOTCH3 and PDGFRB in Myofibroma With Diagnostic and Therapeutic Implications. Int J Surg Pathol. 2020 Apr; 28(2):128-137. View Abstract
59. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8. View Abstract
60. A somatic activating NRAS variant associated with kaposiform lymphangiomatosis. Genet Med. 2019 07; 21(7):1517-1524. View Abstract
61. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma. Clin Cancer Res. 2019 02 15; 25(4):1343-1357. View Abstract
62. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018 03; 31(3):463-473. View Abstract
63. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 01; 19(7):986-996. View Abstract
64. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genet Med. 2017 07; 19(7):787-795. View Abstract
65. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062. View Abstract
66. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016 06 22; 7:11987. View Abstract
67. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 May 01; 2(5):608-615. View Abstract
68. Chromosome 12p abnormalities and IMP3 expression in prepubertal pure testicular teratomas. Hum Pathol. 2016 Mar; 49:54-60. View Abstract
69. Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Cold Spring Harb Mol Case Stud. 2015 Oct; 1(1):a000471. View Abstract
70. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma. J Clin Oncol. 2013 Aug 10; 31(23):2903-11. View Abstract
71. Spreading depression expands traumatic injury in neocortical brain slices. J Neurotrauma. 2005 Feb; 22(2):277-90. View Abstract
Show All Publications Show Fewer Publications